Leukemia Clinical Trials in Chicago

Showing 601-620 of 1,503 trials

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more

Calibr, a division of Scripps Research36 participantsStarted Jan 2021

Duarte, California, United States • San Diego, California, United States • Chicago, Illinois, United States +5 more locations

TERMINATEDPhase 1/22.2 miles

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415

This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors.

Locally Advanced or Metastatic Solid Tumor

Deciphera Pharmaceuticals, LLC70 participantsStarted Jan 2019

San Francisco, California, United States • Santa Monica, California, United States • Chicago, Illinois, United States +6 more locations

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Leukemia Trials in Other Cities

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

MIRACLE of LIFE Study

A Study of ZN-c3 in Patients With Ovarian Cancer

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

First in Human Study of M1069 in Advanced Solid Tumors

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Other Conditions in Chicago